Galiz Research LLC

1. Teva Pharmaceuticals USA, Inc. $5,781,633 246 payments
2. ITI, Inc. $1,248,967 336 payments
3. AbbVie, Inc. $368,501 25 payments
4. Hoffmann-La Roche Limited $290,478 8 payments
5. Biohaven Pharmaceuticals, Inc. $174,206 10 payments
6. Janssen Research & Development, LLC $150,712 5 payments
7. Supernus Pharmaceuticals, Inc. $148,548 23 payments
8. Sumitomo Pharma America, Inc. $103,934 15 payments
9. Allergan Inc. $99,885 14 payments
10. LivaNova USA, Inc. $98,902 46 payments

1. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $4,423,423 188 payments
2. Iti-007-451 $1,248,967 336 payments
3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $1,123,690 35 payments
4. Acute Schizophrenia Study $290,478 8 payments
5. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $234,520 23 payments
6. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $227,779 18 payments
7. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $157,100 9 payments
8. A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. $150,712 5 payments
9. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $148,548 23 payments
10. A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD $83,452 1 payment

1. Patient care $59,672 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.